CGM OK’d During Medical Imaging; All Semaglutide Doses Back; Bariatric Surgery Down

Abbott’s FreeStyle Libre 2 and 3 are the first and only patient-applied continuous glucose monitoring (CGM) systems to be approved for use during medical imaging, the company said.

In related news, the American Diabetes Association released new consensus considerations and good-practice points for use of CGM systems in hospital settings. (Diabetes Care)

A new position paper from the Androgen Society said “it has now been conclusively determined that testosterone therapy is not associated with increased risks of heart attack, stroke, or cardiovascular death.” The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings)

All doses of semaglutide (Ozempic, Wegovy) are now listed as available again, according to an update in the FDA’s drug shortage database. (CNBC)

AstraZeneca’s investigational anti-obesity pill was safe and tolerable in a 72-patient phase I trial, yielding an average 5.8% weight loss within 4 weeks, the company announced at ObesityWeek. (Reuters via MSN)

Also out of the meeting, Viking Therapeutics said its investigational GLP-1/GIP agonist tablet led to an average 6.8% placebo-adjusted weight loss at day 28 in a phase I study. Catch up on more research from ObesityWeek here.

Bariatric surgeries plunged 26% from 2022 to 2023 amid a rise in prescriptions for GLP-1 receptor agonists. (JAMA Network Open)

People with type 2 diabetes who started an SGLT2 inhibitor had a significantly lower recurrent nephrolithiasis event rate compared with those starting on GLP-1 agonists. (The BMJ)

Obesity treatments did not reduce other medical costs over 2 years, an analysis of U.S. health insurance claims showed. (Reuters)

Adding semaglutide to standard of care helped improve liver fibrosis and resolve metabolic dysfunction-associated steatohepatitis (MASH) in a placebo-controlled phase III trial, said Novo Nordisk.

Low-calorie diets involving fasting may help regenerate damaged kidneys, according to a pilot trial of 13 people with chronic kidney disease. (Science Translational Medicine)

The FDA warned against the use of drugs compounded and distributed by Fullerton Wellness in California, including semaglutide and tirzepatide, as they may not be sterile.

Nonsmokers who started menopause between ages 40-44 had a 30% decreased risk of asthma compared with women who started menopause between ages 50-54, suggesting “the role of estrogen in increasing risk of asthma,” said researchers in Menopause.

High intensity exercise may suppress ghrelin levels, a marker of hunger, a study of 14 adults found. (Journal of the Endocrine Society)

Please enable JavaScript to view the

comments powered by Disqus.